{"slug":"hcc","tag":"hcc","variants":["hcc"],"description":"No description yet","count":8,"kinds":{"person":8},"related":[{"slug":"trialist","tag":"trialist","shared":7},{"slug":"biliary","tag":"biliary","shared":3},{"slug":"immunotherapy","tag":"immunotherapy","shared":2},{"slug":"asia","tag":"asia","shared":1},{"slug":"breast","tag":"breast","shared":1},{"slug":"clinician-scientist","tag":"clinician-scientist","shared":1},{"slug":"hepatocellular-carcinoma","tag":"hepatocellular carcinoma","shared":1},{"slug":"japan","tag":"japan","shared":1},{"slug":"liver-cancer","tag":"liver cancer","shared":1},{"slug":"staging","tag":"staging","shared":1}],"records":[{"id":"richard-finn","kind":"person","name":"Richard S. Finn","route":"/people/richard-finn/","tldr":"Led PALOMA-2, which made palbociclib a first-line breast cancer drug, and IMbrave150, which made immunotherapy the standard for liver cancer."},{"id":"josep-llovet","kind":"person","name":"Josep M. Llovet","route":"/people/josep-llovet/","tldr":"Led SHARP, which made sorafenib the first systemic therapy for liver cancer, and created the BCLC staging system."},{"id":"ann-lii-cheng","kind":"person","name":"Ann-Lii Cheng","route":"/people/ann-lii-cheng/","tldr":"Taiwanese oncologist who led the Asia-Pacific sorafenib trial and co-led IMbrave150, the immunotherapy standard for liver cancer."},{"id":"masatoshi-kudo","kind":"person","name":"Masatoshi Kudo","route":"/people/masatoshi-kudo/","tldr":"Japanese hepatologist who led REFLECT, the trial that made lenvatinib a first-line option for liver cancer."},{"id":"ghassan-abou-alfa","kind":"person","name":"Ghassan K. Abou-Alfa","route":"/people/ghassan-abou-alfa/","tldr":"Led HIMALAYA and ClarIDHy, which gave liver cancer a dual-immunotherapy option and biliary cancer its first targeted drug."},{"id":"jordi-bruix","kind":"person","name":"Jordi Bruix","route":"/people/jordi-bruix/","tldr":"Barcelona liver specialist who co-created the BCLC staging system used worldwide to decide how liver cancer is treated, and led STORM, which showed adjuvant sorafenib does not help after curative treatment."},{"id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","route":"/people/robin-kate-kelley/","tldr":"San Francisco oncologist who was lead author of KEYNOTE-966, which showed that adding pembrolizumab to gemcitabine and cisplatin helps people with advanced bile duct cancer live longer."},{"id":"andrew-zhu","kind":"person","name":"Andrew X. Zhu","route":"/people/andrew-zhu/","tldr":"Oncologist who led REACH-2, the first positive biomarker-selected trial in liver cancer, which established ramucirumab for patients with a high alpha-fetoprotein level."}]}